Junevity Secures $10M to Advance Longevity Therapeutics
Slice of Healthcare Team
02/19/2025
Key Highlights
- Junevity raises $10M in seed funding led by Goldcrest Capital and Godfrey Capital.
- RESET platform uses AI and human data to identify transcription factors and develop siRNA therapeutics.
- Initial targets include Type 2 diabetes, obesity, and frailty, with preclinical data showing promising results.
- Therapeutic candidates offer long dosing intervals (3-12 months) for better patient compliance.
- Founded at UCSF, led by top scientists and biotech leaders.
Source: Business Wire
Notable Quotes
“ Junevity’s RESET platform is a big idea that could broadly impact human health by addressing aging at the cellular level. ”
– Dr. John Hoekman, Co-founder & CEO at Junevity
“ My research at UCSF showed the power of targeting transcription factors to restore aged human cells back to health. ”
– Dr. Janine Sengstack, Co-founder & CSO at Junevity
“ The Junevity team has a novel approach, incredible early data, and tremendous potential to treat metabolic and age-related diseases. ”
– Brent Saunders, CEO & Chairman at Bausch + Lomb
Why This Matters
RESET platform siRNA therapeutics reverse cell damage and extend human healthspan
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
